STINGing type I IFN-mediated immunopathology in COVID-19

doi:10.1038/s41590-022-01174-6

Comment

. 2022 Apr;23(4):478-480.

doi: 10.1038/s41590-022-01174-6.

STINGing type I IFN-mediated immunopathology in COVID-19

Evangelos Andreakos¹

Affiliations

Affiliation

¹ Laboratory of Immunobiology, Center for Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. vandreakos@bioacademy.gr.

PMID: 35301509
DOI: 10.1038/s41590-022-01174-6

Comment

STINGing type I IFN-mediated immunopathology in COVID-19

Evangelos Andreakos. Nat Immunol. 2022 Apr.

. 2022 Apr;23(4):478-480.

doi: 10.1038/s41590-022-01174-6.

Author

Evangelos Andreakos¹

Affiliation

¹ Laboratory of Immunobiology, Center for Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. vandreakos@bioacademy.gr.

PMID: 35301509
DOI: 10.1038/s41590-022-01174-6

No abstract available

PubMed Disclaimer

Comment on

SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB.
Neufeldt CJ, Cerikan B, Cortese M, Frankish J, Lee JY, Plociennikowska A, Heigwer F, Prasad V, Joecks S, Burkart SS, Zander DY, Subramanian B, Gimi R, Padmanabhan S, Iyer R, Gendarme M, El Debs B, Halama N, Merle U, Boutros M, Binder M, Bartenschlager R. Neufeldt CJ, et al. Commun Biol. 2022 Jan 12;5(1):45. doi: 10.1038/s42003-021-02983-5. Commun Biol. 2022. PMID: 35022513 Free PMC article.
The cGAS-STING pathway drives type I IFN immunopathology in COVID-19.
Domizio JD, Gulen MF, Saidoune F, Thacker VV, Yatim A, Sharma K, Nass T, Guenova E, Schaller M, Conrad C, Goepfert C, de Leval L, Garnier CV, Berezowska S, Dubois A, Gilliet M, Ablasser A. Domizio JD, et al. Nature. 2022 Mar;603(7899):145-151. doi: 10.1038/s41586-022-04421-w. Epub 2022 Jan 19. Nature. 2022. PMID: 35045565 Free PMC article.

Cited by

The impact of prior SARS-CoV-2 infection on host inflammatory cytokine profiles in patients with TB or other respiratory diseases.
Cottam A, Manneh IL, Gindeh A, Sillah AK, Cham O, Mendy J, Barry A, Coker EG, Daffeh GK, Badjie S, Barry S, Owolabi O, Winter J, Walzl G, Sutherland JS. Cottam A, et al. Front Immunol. 2023 Dec 21;14:1292486. doi: 10.3389/fimmu.2023.1292486. eCollection 2023. Front Immunol. 2023. PMID: 38179046 Free PMC article.
COVID-19. Biology, pathophysiology, and immunology: a pathologist view.
Chilosi M, Doglioni C, Ravaglia C, Piciucchi S, Dubini A, Stefanizzi L, Poletti V. Chilosi M, et al. Pathologica. 2023 Oct;115(5):248-256. doi: 10.32074/1591-951X-954. Pathologica. 2023. PMID: 38054899 Free PMC article. Review.
Cytoplasmic DNAs: Sources, sensing, and roles in the development of lung inflammatory diseases and cancer.
He X, Sun Y, Lu J, Naz F, Ma S, Liu J. He X, et al. Front Immunol. 2023 Apr 12;14:1117760. doi: 10.3389/fimmu.2023.1117760. eCollection 2023. Front Immunol. 2023. PMID: 37122745 Free PMC article. Review.
Phase-separated nucleocapsid protein of SARS-CoV-2 suppresses cGAS-DNA recognition by disrupting cGAS-G3BP1 complex.
Cai S, Zhang C, Zhuang Z, Zhang S, Ma L, Yang S, Zhou T, Wang Z, Xie W, Jin S, Zhao J, Guan X, Wu J, Cui J, Wu Y. Cai S, et al. Signal Transduct Target Ther. 2023 Apr 26;8(1):170. doi: 10.1038/s41392-023-01420-9. Signal Transduct Target Ther. 2023. PMID: 37100798 Free PMC article.
Blood transcriptome responses in patients correlate with severity of COVID-19 disease.
Wang Y, Schughart K, Pelaia TM, Chew T, Kim K, Karvunidis T, Knippenberg B, Teoh S, Phu AL, Short KR, Iredell J, Thevarajan I, Audsley J, Macdonald S, Burcham J, McLean A; PREDICT-19 consortium; Tang B, Shojaei M. Wang Y, et al. Front Immunol. 2023 Jan 20;13:1043219. doi: 10.3389/fimmu.2022.1043219. eCollection 2022. Front Immunol. 2023. PMID: 36741372 Free PMC article.

See all "Cited by" articles

References

1. Domizio, J. D. et al. Nature 603, 145–151 (2022). - DOI
1. Neufeldt, C. J. et al. Commun Biol 5, 45 (2022). - DOI
1. Blanco-Melo, D. et al. Cell 181, 1036–1045 e1039 (2020). - DOI
1. Lucas, C. et al. Nature 584, 463–469 (2020). - DOI
1. Galani, I. E. et al. Nat. Immunol. 22, 32–40 (2021). - DOI

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- MedlinePlus Health Information

[1] Domizio, J. D. et al. Nature 603, 145–151 (2022). - DOI

[2] Domizio, J. D. et al. Nature 603, 145–151 (2022). - DOI

[3] Neufeldt, C. J. et al. Commun Biol 5, 45 (2022). - DOI

[4] Neufeldt, C. J. et al. Commun Biol 5, 45 (2022). - DOI

[5] Blanco-Melo, D. et al. Cell 181, 1036–1045 e1039 (2020). - DOI

[6] Blanco-Melo, D. et al. Cell 181, 1036–1045 e1039 (2020). - DOI

[7] Lucas, C. et al. Nature 584, 463–469 (2020). - DOI

[8] Lucas, C. et al. Nature 584, 463–469 (2020). - DOI

[9] Galani, I. E. et al. Nat. Immunol. 22, 32–40 (2021). - DOI

[10] Galani, I. E. et al. Nat. Immunol. 22, 32–40 (2021). - DOI

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

STINGing type I IFN-mediated immunopathology in COVID-19

Affiliation

STINGing type I IFN-mediated immunopathology in COVID-19

Author

Affiliation

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical